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Background: Many cancer patients and survivors experience permanent and life-debilitating effects, such as 
ototoxicity, from treatment. Ototoxicity manifests as high frequency hearing loss and tinnitus which can have a 
detrimental effect on the quality of life of those affected. Currently, there is little information and support 
offered to these patients who experience ototoxicity, potentially leading to many being undiagnosed and 
untreated.  
Objective: To explore the extent of ototoxic side effects, such as hearing loss and tinnitus and their impact on 
cancer patients following chemotherapy treatment. Secondary objectives included detecting the time periods of 
onset and duration of the ototoxicity and identifying what support was available to this population. 
Methods: Posts from publically available online forums were thematically analysed using the guidelines from 
Braun and Clarke. A coding manual was iteratively developed to create a framework for the analysis of the 
ototoxicity experience amongst the cancer population. 
Results: A total of nine relevant online forums were identified, consisting of 86 threads and 570 posts from 377 
members. Following the bottom-up thematic analysis, six major themes were identified: Nature of Ototoxicity, 
Time of Experienced Ototoxicity, Information on Ototoxicity, Quality of Life, Therapies and Online Social 
Support.  
Conclusions: There was a significant number of reports expressing concerns about the lack of information on 
the risk of ototoxicity. More support for those suffering is needed, for example, improved inter-departmental 
communication between oncology and audiology services could optimise patient care. Patients should also be 
encouraged to communicate with their healthcare professionals about their ototoxicity and relay how their 
quality of life is impacted in order to access appropriate or specialist support. Tinnitus was the most common 
concern and was associated with distress. Hearing loss was less common and was associated with fear and 
employment issues. Those who reported pre-existing conditions were fearful about worsening their condition as 








Although there are an estimated 17.5 million cancer cases per year worldwide, the development of screening 
programmes and improved diagnostics have contributed to an increase in survival rates [1,2]. Whilst the current 
overall 5 year survival rate is 67 %, this means that many more cancer survivors are now living with the late 
effects of cancer treatment, such as peripheral neuropathy and ototoxicity [3]. Ototoxicity is defined by 
American Speech-Language-Hearing Association (ASHA) as a decrease in hearing thresholds relative to 
baseline testing and indicates evidence of damage in hearing caused by medication [4]. Platinum-based 
chemotherapy, e.g. cisplatin, whilst a highly effective antineoplastic agent, is known to cause peripheral 
neuropathy and ototoxicity (resulting in tinnitus and hearing loss) [5]. Tinnitus is defined as the manifestation of 
a conscious perception of an auditory sensation without a corresponding external stimulus [6,7]. 
These effects can potentially have a significant impact on quality of life. Tinnitus, for example, is associated 
with sleep difficulties, and hearing loss is associated with dementia [8,9]. A deeper understanding of the impact 
of these long term consequences of cancer treatments can have on quality of life (QoL) can improve long term 
symptom management in patients living with the debilitating effects of cancer treatment [10,11].  
There is a lack of information on the prevalence and effect of ototoxicity due to the underreporting of ototoxic 
events and few longitudinal studies [12,13]. The literature advising on the diagnosis, grading systems and 
management of ototoxicity is heterogeneous across studies resulting in poor quality information being available 
[13–15]. Consequently, this has had a substantial effect on the quality of support offered for patients, as there is 
no standard protocol or guidance for clinicians to follow. 
The increase in popularity of using the internet allows anyone to access healthcare information instantly and can 
potentially improve patients’ knowledge and help with treatment decisions [16,17]. Technological advances 
have meant that this method of research is becoming increasingly used within medicine [18]. Although this 
methodology has not been used for ototoxicity, there has been thematic analysis carried out on online group 
discussions in Parkinson’s disease and men’s fertility issues [19,20]. There has also been, although inconclusive, 
evidence to show that online support in cancer patients has a positive effect [21]. By exploring online healthcare 
forums (OHFs), the impact on quality of life from ototoxicity can be analysed. OHFs are a way in which 
patients can contribute to a range of personal health-related discussions openly with one another by grouping 
various threads on a specific topic [16,22,23]. Individuals suffering from long-term effects of treatment are 
significantly more likely to participate in this online community to discuss health concerns [24]. 
Aims and Rationale 
Approximately 14.2% of long-term cancer survivors live with disabilities directly caused by their cancer 
treatment and its toxic nature [10,25]. Clinical reports of patients may not reflect the true incidence or severity 
of the late effects caused by treatments, specifically ototoxicity. In many cases, patients ask medical questions or 
share experiences online that they could not in person. Yet this potentially rich source of information has not yet 
been explored. Thus, the aim of this study was to explore the true demographic and the impact on quality of life 
of ototoxic effects caused by cancer treatment via analysis of OHF discussions. Secondary objectives were to 
explore the time course of ototoxicity occurrence in relation to treatment, whether the adverse effects were 
reported as temporary or permanent, and which means of support patients had access to and used. This research 
has the potential to significantly inform clinical and social after-care of those who have been treated for cancer.  
Methods 
Ethical Considerations 
Ethical approval for the study was obtained by the University of Nottingham, School of Medicine Ethics 
Committee. Although informed consent was not required in this study as the information was available in the 
public domain, all members’ personal details were kept anonymous to maintain confidentiality and protect 
privacy [26].  
Quotes used were extracted as part of a longer, original post. Details which would allow the member to be 
traced were excluded. Risk to forum users was deemed to be minimal.  
Sample and Inclusion Criteria 
Relevant and representative forums were identified using the four most common search engines, i.e. Google, 
Yahoo!, AOL and Bing [27]. Search terms included combinations of “impact”, “effect”, “forum”, “discussion”, 
“hearing loss”, “tinnitus”, “chemotherapy” and 
“cancer”. Inclusion criteria were (1) forum did 
not require membership (i.e. publicly available) 
and (2) the forum content was in the English 
language [28]. The first search page was 
screened for results and there were no date 
restrictions for the searches. Relevant OHFs 
were manually extracted onto Excel and the 
threads within these OHFs were screened. A 
thread was considered relevant when the post 
itself mentioned hearing loss and/or tinnitus, and 
either cancer or chemotherapy, either by asking a 
question or offering support. The relevant 
threads were extracted ready for thematic 
analysis.  
Thematic analysis 
The data extraction and the thematic coding 
strategy were based on the Gao et al., (2017) and 
Braun and Clarke (2006) methodology. Whole 
threads were screened and the messages deemed 
irrelevant or which had too few replies were 
excluded (Figure 1). Messages were then 
extracted for thematic analysis. The number of 
members posting on the forums was quantified 
and the threads were randomised using computer 
software. Following the “bottom-up” strategy, 
open coding was performed by making initial 
comments on the first 100 messages, from which 
a pilot coding manual was produced. For 
example, the quote “The most worrying thing I 
have come across is that I may suffer changes to 
my hearing, I am petrified.” was described as a 
fear of developing ototoxicity. This was 
followed by grouping similar descriptions 
together into codes, which fit into categories and finally, arranging these into clearly defined themes [29]. Using 
the example quote, this was defined as a “General Fear” code and grouped into the “Emotions” category in the 
“Quality of Life” theme. Two researchers (SP and JT) independently coded the remaining randomised messages 
against the coding manual and compared results. Any differences were discussed and the coding manual was 
reorganised and developed accordingly. Following this discussion, the two researchers (SP and JT) agreed a 
final coding manual and the remaining messages were coded and quantified to assess which topics people 
discussed most frequently.  
Results 
Description of Included Forums 
The search found 11 OHF websites varying in popularity. This was further narrowed to nine following the 
elimination of duplicates (Table 1). A total of 34 OHFs were identified and 86 threads were included in the final 
analysis. The number of messages within the threads varied greatly. For the larger threads, only the most 
relevant messages were extracted. Over 3000 messages were screened and a total 570 messages were manually 
extracted for the final analysis. 
The range of numbers of members in each thread posting about ototoxicity ranged from one to 17, with 56 
members seeking information and sharing their experiences in multiple threads and forums. The forums 
themselves varied in popularity, however the number of active members was not always publically available. A 
total of 377 members were responsible for the 570 messages extracted (Table 1). The geographical information 
 
Figure 1. Flowchart representing the methodology and strategy of the OHF 
screening and analysis. (OHF: Online healthcare forum) 
 
of the posts was not always available although consisted mainly of the UK and USA, however there were 
threads based in Australia, New Zealand and South Africa.  
Table 1. The number of threads extracted, the number of messages extracted and the range and total of participants and members posting 













      
Forum 1 8 105 1-16 6 50 
Forum 2 5 41 3-10 4 32 
Forum 3 18 122 2-12 14 69 
Forum 4 9 68 3-17 11 49 
Forum 5 19 80 1-5 7 55 
Forum 6 5 14 1-8 1 14 
Forum 7 8 37 2-7 6 27 
Forum 8 3 21 4-12 1 20 
Forum 9 11 82 3-14 6 61 
Total 86 570 1-17 56 377 
Thematic Analysis 
Forty-two final codes were generated from which to interpret the forum messages by following the Braun and 
Clarke methodology (Figure 3). The names of each category and theme emerged through discussion of words, 
terms that the two researchers thought reflected the set of codes, which were then reviewed by all authors. The 
six overarching themes were (1) Nature of Ototoxicity, (2) Time of Experienced Ototoxicity, (3) Information on 
Ototoxicity, (4) Quality of Life, (5) Therapies, and (6) Online Social Support.   
Figure 2. The themes, subthemes and codes found within the forum messages and the number of times the codes were reported (n). Themes include the 
Nature of Ototoxicity (n= 724), Time of Experienced Ototoxicity (n= 225), Information on Ototoxicity (n= 216), Quality of Life (n= 547), Therapies 
(n= 347), Online Social Support (n= 478). 
Results and Discussion 
The Nature of Ototoxicity 
The Nature of Ototoxicity theme was the most discussed within the forums (n= 724). It consisted of describing 
and categorising the ototoxic symptoms experienced. This theme consisted of; Tinnitus (n= 458), Hearing (n= 
233) and Imbalance (n= 33). The Tinnitus subtheme entailed the personal perception of tinnitus as described by 
the members. Over 80% (n= 458) of the 570 messages within the forums reported some experience of tinnitus, 
suggesting that tinnitus is a significant occurrence within this population.  
“I reported to my oncologist that I experience the loudest high pitched ringing that makes me put my 
hands over my ears!” (User X, Forum 7) 
The most common aspects of tinnitus described, in addition to a ringing sensation (General Tinnitus n= 288), 
were Pulsatile Tinnitus (n= 36) Continuous Tinnitus (n= 23), Intermittent Tinnitus (n= 29), Unilateral Tinnitus 
(n= 58) and Loud Tinnitus (n= 24). Users reported Pulsatile Tinnitus (n= 36) as a “heartbeat thumping” or 
“whooshing sounds” in the ear. Pulsatile tinnitus, although no known research has been conducted on the 
association with cancer treatments, has been thought to be of a vascular origin and can be synchronised with the 
heartbeat [7,30]. Unilateral Tinnitus seemed to occur more in the left ear (n= 34) compared to the right ear 
(n=24). Previous research reported ~15 % of patients treated with cisplatin had experienced unilateral tinnitus 
[31]. A similar total of 13 % of forum messages mentioning Tinnitus were found to be Unilateral Tinnitus, 
which correlates with the literature.  
“I just came out of the ward after my first treatment cycle, I feel okay in myself apart from this constant 
high ringing in my left ear.” (User A, Forum 4) 
Within the Hearing subtheme, Hearing Loss (n= 226) was commonly reported. Only seven members reported 
Reduced Tolerance to Sound. Hearing Loss was mentioned by users prior to receiving treatment and being 
fearful of the deficit, in addition to complaints of already experiencing hearing loss due to chemotherapy. 
Furthermore, multiple users expressing hearing loss mentioned already having a form of hearing deficit which 
had worsened.  Although there has been research carried out reporting hearing loss following chemotherapy, it 
is worth noting that Reduced Tolerance to Sound has not previously been reported in the literature as an adverse 
effect, and as such further research is warranted [32–34].  
“The other day I had a hearing test which confirmed that cisplatin has damaged my hearing. I can no 
longer hear well.” (User Y, Forum 7)  
Within the OHFs, there were also members reporting Imbalance, which were mainly discussed in threads 
associated with breast cancer (n= 33). Imbalance seemed heavily associated with Femara and Taxol treatments. 
Vertigo has been reported in a study investigating the aetiology in 36 breast cancer survivors, however is rarely 
associated with ototoxicity within medical literature [35]. 
“I am currently getting weekly Taxol treatments with Carboplatin. I have had acute episodes of sudden 
vertigo. Both times I was reading a book and suddenly felt the room spinning. The feeling lasts about 10 
seconds but is very intense! I have no previous history with vertigo.” (User C, Forum 1)  
Time of Experienced Ototoxicity 
The Time of Experienced Ototoxicity (n= 225) was variable within the OHFs. Although members described 
their Onset as Pre-existing prior to Treatment (n= 39), During Treatment (n= 78) or Late Onset (n= 22), specific 
times were also noted. For example, there were reports of tinnitus and hearing loss occurring from the first 
cycles (n= 9, 5, 3 for cycles 1, 2 and 3 respectively) to occurring 2 years post-treatment. It is thought pre-
existing hearing deficits increases the risk of experiencing ototoxicity [36]. However, only 28.1 % (n= 39) of 
those mentioning the onset of ototoxicity admitted to having prior hearing deficits [37]. Those with pre-existing 
conditions mainly shared their concerns about further damage. 
“This is worrying me, I am due to start treatment but I already have congenital severe hearing loss 
which is corrected by the use of hearing aids. The thought that chemo could make things worse is a 
real issue for me. The thought of chemo is scary enough but the thought of further damage to my 
hearing is scarier still.” (User B, Forum 2) 
Many members believed tinnitus would be temporary and expressed shock when it became permanent. 
Furthermore, members sought validation that what they were experiencing was an adverse effect and not the 
reoccurrence of cancer. From those who reported their Duration of ototoxicity, 71 % (n= 61) reported having 
Permanent tinnitus. 
“It’s just over 10 months since I finished treatment. I had bad tinnitus during treatment but it 
completely disappeared for months. I've noticed that in the past few weeks my tinnitus is back 
intermittently maybe 2/3 times a day. Has anyone else had tinnitus reappearing after months and 
months of nothing?” (User Z, Forum 5) 
It is worth noting that many users did not share the duration of their tinnitus. Further research is needed to 
identify possible risk factors of permanent tinnitus, although it is known that tinnitus caused by chemotherapy is 
associated with age and a higher accumulative dose [5,38–41]. Users did not commonly report their age or dose 
of treatment, therefore it would be difficult to conclude if this population reflects previous studies. Overall, 
members appeared to remain positive, frequently sharing tips and advice to help others, despite posting how 
permanence of tinnitus affected their quality of life. 
“My overall hearing loss has been profound but it’s a side effect of Cisplatin I'm afraid. I'm not expecting it 
to go away, and I've been told it's likely to be permanent. Sorry not to be more positive.” (User C, Forum 5) 
Information on Ototoxicity 
One of the discussion topics reported throughout the different forums was the Information on Ototoxicity (n= 
216). This theme consisted of the Attribution of Chemotherapy to Ototoxicity (n= 158) and Dissatisfaction with 
the Information Provided (n= 58). The Attribution of Chemotherapy to Ototoxicity consisted of members who 
Associated Hearing Loss with Old Age (n= 18), or believed that because it is a fairly Rare (n= 16) toxic effect of 
chemotherapy that there must be another cause. This could be due to denial from the patients or simply a lack of 
knowledge on ototoxicity.  
“These days I have ringing in my ears. It’s probably due to my old age.” (User A, Forum 9) 
The majority of members, however, did see an Association between Chemotherapy and Ototoxicity (n= 124). 
The members who had more knowledge on ototoxicity were vocal in sharing what they had been told by 
healthcare professionals, urging those who had not made the association to see an audiologist or their GP. 
Furthermore, many members expressed some Dissatisfaction with the Information Provided (n= 58). Members 
shared their anger, disappointment and Dissatisfaction with Healthcare Professionals and Lack of Information 
(n= 50), because they had not been warned about ototoxicity. 
“Straight after my first cycle, I started suffering from a ringing noise in both ears. I told my oncologist 
about it and she just made a note, and sent me off for the third dose without saying a word! I was not 
warned about this and don't get the impression that anyone cares other than me.” (User C, Forum 2) 
There appeared to be a lack of communication between patients and professionals, which was reported 
frequently throughout the forums, despite there being a significant number of studies aiming to raise awareness 
of ototoxicity [42]. Members expressed having felt ignored and not taken seriously during consultations.  
 “I think they don't reveal all of these things to us because they don't want to scare us away from doing 
the chemo. When I first started having tinnitus all I got was "I've never seen a case from carboplatin" 
like I'm making it up. I looked back through all my papers they gave me at first for the side effects and 
there was one notation about a rare side effect: 'hearing changes'. I really feel like I didn't have all the 
information I needed at the time I was making my decisions. It does make you wonder what else they 
haven’t told us.” (User W, Forum 1) 
In contrast, members also confessed to Withdrawal of Information (n= 7) by lying or not telling their clinicians 
about the severity of their tinnitus and hearing loss because they feared having to compromise the dosage of 
their chemotherapy, and feared morbidity. This could have detrimental impacts on both patients and clinicians 
as it reduces any reliable information reported.  
“I’m worried that if I tell the truth about the months of diarrhoea and headaches and tinnitus and the 
newer extreme tiredness, they'll say I'm too old and fragile to get any more treatment and dump me 
from the trial.” (User Y, Forum 1) 
There was only one message expressing how Overwhelming Information (n= 1) stopped them from listening to 
the information provided, leading to that individual becoming fearful of undergoing treatment. 
Quality of Life 
Another main theme was the severity of ototoxicity and the impact this had on Quality of Life (n= 547). 
Members discussed both Practicalities (n= 119), Coping Strategies (n= 65) and Emotions (n= 147) associated 
with how their Quality of Life was compromised. Numerous messages implied the symptoms were mild, with 
many members saying they had Manageable Symptoms (n= 43) which they could easily cope with or ignore, 
such as: 
“Most of the time when I am busy, I don't notice it [tinnitus], but as you probably know, when you 
become aware of it, it is hard to ignore. I hope you are lucky and your goes away.” (User H, Forum 5) 
However, most users reported in abundance how their Day to Day Life (n= 62) was affected by ototoxic effects. 
Many members shared concerns over how their hearing loss affected their relationship with their partners and 
family members, which could be distressing and isolating.  
“I'm three years post chemo and now have tinnitus in my left ear which is getting worse. I don't recall 
being told chemo could damage ear and it drives me mad. Will it ever go? Sound sets it off so if I sit in 
silence its okay but it's affecting my relationship now. I don’t know what to do.” (User F, Forum 2) 
Research has been conducted on how tinnitus and hearing loss affects quality of life, however it has not been 
expanded into the population facing cancer treatment and survivorship [43–45]. Additionally, the few studies 
exploring quality of life affected by tinnitus do not go into depth into what aspects of life ototoxicity effects 
[6,46]. Therefore, by exploring these messages from the forums, specific aspects of quality of life affected by 
ototoxicity can be identified. This will help develop a relevant and tailored support system for these patients.   
 “I cannot hear at all in my left ear ever since having chemotherapy. I have been fitted, aged 39, with a 
hearing aid but I have very short hair as a result of chemo, so they show and it affects my self-esteem. I 
don't sleep with the aids in so I can’t hear my baby when she wakes at night which I find really 
distressing. I feel about 90.” (User S, Forum 2) 
Another concern amongst members was the effect ototoxicity had on Employment (n= 14). Specifically, 
professional musicians shared their fear over losing the ability to play music. Members spoke of the risk of 
losing their hearing being catastrophic for their employment and even mentioned early retirement. Most of the 
questionnaires used to assess Quality of Life and ototoxicity do not mention the impact on employment. This 
area needs to be explored clinically, specifically in those who critically need to hear to be employed, such as 
musicians.  
“Better than dead? At this point, I'm wondering. I cannot work with this condition because my job 
requires proper hearing. Hearing loss and this constant tinnitus is life-changing, far more than having 
cancer is. This has me worried more than living with cancer. I'm wondering if I'll ever have another 
day where I can hear clearly and be a productive member of society.” (User Z, Forum 4) 
One of the main issues faced with ototoxicity was how it acted as a Reminder of Cancer (n= 9). Although 
members mentioned successfully managing the tinnitus and hearing loss, it acted as a permanent reminder of 
what difficulties they had been through. There was a sense of General Fear (n= 49) experienced across the 
forums, as members frequently discussed being fearful of losing their hearing and how this could affect their 
life. In fact, many people discussed concerns over safety and how this gave them anxiety. As mentioned 
previously, these aspects of life are rarely included in questionnaires, therefore are rarely reported in the 
literature.  
“I cannot hear the door opening, food cooking, the television or radio and comprehend what they're 
saying. It's dangerous. I never realized how much we rely on the sounds of cooking. No more multi-
tasking in the kitchen, I have to stand and watch the stove top now.” (User A, Forum 9) 
Within this sense of fear, there was a specific Fear of Permanence (n= 36) of the ototoxic effects. There were 
frequent concerns over how long the hearing loss and tinnitus would last and if they would ever recover normal 
hearing. Currently, there is little knowledge about the duration of ototoxicity and no predicting factors, which 
could further induce this fear in patients.  
“I completed all of my chemotherapy cycles and since then I have lost a lot of hearing and also have 
ringing in my ears. Has anyone experienced this and gained hearing back?  I am hoping since I only 
finished a month ago I will improve, but no one is telling me anything. If anyone has a positive story I 
would love to hear about it, to give me hope.” (User F, Forum 3) 
Associated with fear was Distress and Severe Impact of Quality of Life (n= 53). There were messages which 
described hearing loss and tinnitus as “unbearable, severe and extremely bothersome”, which is consistent with 
the current literature on how tinnitus and hearing loss affects quality of life in the general population [47]. 
However, managing chemotherapy-induced ototoxicity in addition to coping with cancer can be extremely 
distressing, therefore appropriate multi-disciplinary support should be considered urgent.  
“Tinnitus is controlling my life right now and I don’t know what to do. I am suicidal and keep thinking 
of the best way to end this misery once and for all. I don’t know how long I can keep this up. I wish I 
was strong like all of you in this forum but I am so weak and fragile right now. I gave up on God ever 
existing cos if he did exist then none of us would be suffering like this right now and diseases such as 
cancer would not exist.” (User E, Forum 6) 
How members coped with ototoxic effects varied greatly throughout the forums. Three codes formed the Coping 
Mind-sets subtheme, Acceptance of Ototoxicity (n= 23), Survival Mind-set (n= 33) and the Inability to Cope (n= 
9). Messages on Acceptance and having to “learn to live with tinnitus” varied from being positive to resentful. 
“I'm afraid I do not know how to say this without being blunt, but would you really rather die than live 
with some permanent tinnitus from your cancer? Most of us have a few souvenirs from cancer, I think 
that is better than dying.” (User G, Forum 4) 
“I finished all my chemotherapy 6 months ago and I am still suffering from side effects. Numbness in 
my fingers and toes, pain in my feet and calves and hearing loss. I AM happy to be alive, but I can't 
shake off the dissatisfaction I have with the body treatment left me with.” (User D, Forum 3) 
The most frequent Coping Mind-set was the Survival Mind-set. People shared thoughts like “worry about the 
cancer now and the side effects later” within this Survival Mind-set and tended to promote this view of ignoring 
any side effects until after the cancer was in remission. This mind-set could in fact be partially responsible for 
the underreporting of toxicities in clinical trials, therefore having negative clinical implications on research. 
Patients should be encouraged to speak openly about their experienced toxicities.  
“The most important thing is that the chemotherapy worked, it just seems silly for us to be moaning 
about a bit of tinnitus.” (User P, Forum 5) 
Although not many, there were members with an Inability to Cope. These appeared to be extremely depressed 
and seemed to need urgent care and advice, such as counselling.  
“I have had the Cisplatin dose reduced 20 percent for the second round due to the ringing and hearing 
loss. I can't seem to find anything positive to report. Most say it’s permanent, including my oncologist 
and audiologist. I may be forced to stop treatment if mine gets any worse because I'd rather be dead 
than deaf.” (User I, Forum 4) 
By supporting these patients prior to their tinnitus and hearing loss worsening, the health service and patients 
alike could potentially save on mental health costs. Moreover, aspects such as sleep, employment and 
relationships are all major parts of life and when these are affected it can have a devastating effect on a whole 
population. It has been reported that those with more comorbidities seem to experience a higher incidence and 
severity of tinnitus, which could factor in to having a lower quality of life [46]. Research is needed to predict 
and identify patients who need more support, in order to prevent this detrimental effect on their mental health. 
Therapies 
Members discussed which Drug (n= 239) treatment regimens they were on, such as Cisplatin (n= 143), 
Carboplatin (n= 56), Oxaliplatin (n= 2) and Non-Platinum Drugs (n= 38). Some messages expressed simply 
their regime and their adverse effects, without mentioning how it affected their quality of life. It is difficult to 
conclude how these members cope and are affected by ototoxicity. 
“I have severe hearing loss and osteoporosis from carboplatin. I am only 21.” (User G, Forum 3) 
There were few members discussing the Diagnostics (n= 12) they experienced, with an almost equal number of 
members stating they had No Baseline Test (n= 5) compared to having had a Baseline Test (n= 7). This 
correlates with studies having found that baseline tests are not as frequently carried out as suggested [48]. 
“I had a baseline reading before chemo. Showed mild age related hearing loss, but I could still hear 
compared to now!” (User H, Forum 9) 
“I didn't have a baseline test before starting chemo because no one suggested it.” (User L, Forum 4) 
A subtheme which was relatively abundant within the OHFs was Medical Adjustments (n= 96). This involved 
many of the members having to wear Hearing Aids (n= 51) due to the ototoxic effects, and others Adjusting 
Treatment Regimens due to Ototoxicity (n= 45) which involved anything from changing the drug, lowering the 
dose or stopping treatment altogether to prevent any further hearing loss or tinnitus. This code was heavily 
associated with Fear of Permanence and Distress.  
“The hearing test I had told the audiologist it was permanent. I got hearing aids about 3 months after 
treatment was over. I wasn't told hearing loss was a possibility. Every time I went to a doctor, I asked 
the doc to look at my ears. Finally, one said, see the audiologist. I was crushed - I was only 45 at the 
time. I did get the hearing aids, and they help so much.” (User C, Forum 3) 
Online Social Support 
Finally, there was a sense of Online Social Support (n= 478) which included support expressed by members to 
create a community and develop friendships. From the 570 different forum messages, only one message was 
interpreted as negative. The Advice and Tips (n= 299) subtheme involved members Asking for Advice (n= 99) 
and Offering General Advice (n= 200) from how to ignore tinnitus to which hearing aid to use. There were many 
messages which offered Positive Support (n= 132) and used terms such as You’re not Alone (n= 47). 
“I hadn't realised how many others have developed Tinnitus too - nice to be in good company.” (User 
D, Forum 9) 
 
A significant number of patients expressed concerns over not been adequately informed about the true risk of 
ototoxicity. Although some members expressed having being warned of the risks, they reported that the 
information given to them was vague and unclear. Some spoke about referrals to audiology departments and 
seemed satisfied with this level of support. It could be suggested that more inter-department communication be 
made to optimise patient care. Furthermore, information available to patients on ototoxicity could be improved 
by updating the chemotherapy leaflets. Patients may feel overwhelmed with the amount of information given to 
them, thus the information should be shared on a case-by-case basis. It is noteworthy, however, that from the 
570 messages analysed only one message expressed feeling overwhelmed by the information about ototoxicity.  
Members who were fearful of losing hearing were those who had pre-existing conditions. This could be because 
their quality of life has already been impacted, whereas those posting who had no previous experience with 
hearing loss or tinnitus would not know how exactly their quality of life may be affected. For many, ototoxicity 
is not an immediate concern when thinking of chemotherapy. However, once the immediate adverse effects 
subside, ototoxicity remains as a distressing reminder of their cancer. Patients should be encouraged to 
communicate with their healthcare professionals about their ototoxicity and relay how their quality of life is 
impacted in order to access the appropriate support.  
There were more reported concerns over tinnitus than any other ototoxic effect. Tinnitus was also associated 
with distress and the inability to cope. Members posted concerns over sleep, their relationships and their mental 
health. More clinical interventions, such as cognitive behavioural therapy, should be readily available to this 
population. Furthermore, hearing loss was common within the OHFs but was more associated with fear of 
losing hearing, fear over personal safety and fear of hearing loss impacting on employment. 
 
Limitations of the Current Study 
As this research was observational and exploratory, there was no way of quantitatively measuring quality of life. 
The posts were subject to misinterpretation, although two researches were involved in analysis to minimise the 
risk of this potentially occurring. Although OHFs are popular within communities, this sample is not necessarily 
representative of the population, as only two of the forums had information on number of members and active 
threads, therefore it is difficult to draw conclusions on the exact population. . Only those who have internet 
access and are inclined to voluntarily share personal information participated. It is also possible that those who 
post on forums are those with the most severe worries, and those whose questions have not been answered by 
healthcare professionals meaning they seek advice online. Furthermore, gender, age, and geographical location 
of the members were mainly unknown. Therefore, no analysis could be undertaken on these factors. 
Conclusions 
In conclusion, ototoxicity has a significant burden on the quality of life in those suffering from cancer. More 
information and support should be available to this population in order to help manage these long term 
symptoms. Tinnitus was the most frequently reported ototoxic effect within the OHF, followed by hearing loss. 
The ototoxic effects were associated with lower quality of life, fear, isolation, depression and frustration that 
patients were not warned enough about these effects.  
Acknowledgements 
This report is independent research by the National Institute for Health Research Biomedical Research Centre 
Funding Scheme. The views expressed in this publication are those of the author(s) and not necessarily those of 
the NHS, the National Institute for Health Research or the Department of Health. 
Conflicts of Interests 
None declared. 
Abbreviations 
OHF: Online Health Forums 
QoL: Quality of Life 




1.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians [Internet] 
2018 Jan 1 [cited 2018 Mar 16];68(1):7–30. [doi: 10.3322/caac.21442] 
2.  Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians [Internet] 
2015 Jan 1 [cited 2017 Dec 20];65(1):5–29. [doi: 10.3322/caac.21254] 
3.  Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, D Global, Regional, and 
National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-
Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. JAMA Oncology [Internet] 2017;3(4):524. 
PMID:27918777 
4.  Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: 
Underestimating a commonly occurring toxicity that may influence academic and social development. 
Journal of Clinical Oncology 2005;23(34):8588–8596. PMID:16314621 
5.  Oldenburg J, Fossa SD, Dahl AA, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term 
neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer 
survivors. Quality of Life Research [Internet] 2006 Jun 27 [cited 2018 Jan 12];15(5):791–800. 
PMID:16721639 
6.  Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M. Long-term 
ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Gynecologic Oncology 
[Internet] Elsevier Inc.; 2017;145(1):148–153. PMID:28202195 
7.  Baguley D, McFerran D, Hall D. Tinnitus. The Lancet [Internet] Elsevier; 2013 Nov 9 [cited 2018 Mar 
14];382(9904):1600–1607. PMID:23827090 
8.  Zeman F, Koller M, Langguth B, Landgrebe M. Which tinnitus-related aspects are relevant for quality 
of life and depression: results from a large international multicentre sample. Health and Quality of Life 
Outcomes [Internet] BioMed Central; 2014 Jan 14 [cited 2018 Mar 16];12(1):7. [doi: 10.1186/1477-
7525-12-7] 
9.  Gurgel RK, Ward PD, Schwartz S, Norton MC, Foster NL, Tschanz JT. Relationship of hearing loss and 
dementia: a prospective, population-based study. Otology & neurotology : official publication of the 
American Otological Society, American Neurotology Society [and] European Academy of Otology and 
Neurotology [Internet] NIH Public Access; 2014 Jun [cited 2018 Jul 30];35(5):775–81. 
PMID:24662628 
10.  GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-
years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a 
systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016;388(10053):1603–
1658. PMID:26475004 
11.  Nonnekens J, Hoeijmakers JH. After surviving cancer, what about late life effects of the cure? EMBO 
Molecular Medicine [Internet] 2017;9(1):4–6. [doi: 10.15252/emmm.201607062] 
12.  Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of Life in Long-
Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study. CancerSpectrum Knowledge 
Environment [Internet] Oxford University Press; 2002 Jan 2 [cited 2018 Jan 3];94(1):39–49. [doi: 
10.1093/jnci/94.1.39] 
13.  Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity 
criteria. European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg; 2017;274(3):1187–
1196. PMID:27245751 
14.  Golder S, Loke Y. Search strategies to identify information on adverse effects: a systematic review. 
Journal of the Medical Library Association : JMLA [Internet] 2009;97(2):84–92. PMID:19404498 
15.  Chang KW. Clinically accurate assessment and grading of ototoxicity. Laryngoscope 
2011;121(12):2649–2657. PMID:22109766 
16.  Gao J, Liu N, Lawley M, Hu X. An Interpretable Classification Framework for Information Extraction 
from Online Healthcare Forums. Journal of Healthcare Engineering [Internet] Hindawi; 2017 Aug 3 
[cited 2017 Nov 1];2017:1–12. [doi: 10.1155/2017/2460174] 
17.  Im E-O, Chee W. An online forum as a qualitative research method: practical issues. Nursing research 
[Internet] NIH Public Access; 2006 [cited 2017 Nov 8];55(4):267–73. PMID:16849979 
18.  Tan SS-L, Goonawardene N. Internet Health Information Seeking and the Patient-Physician 
Relationship: A Systematic Review. Journal of medical Internet research [Internet] JMIR Publications 
Inc.; 2017 Jan 19 [cited 2018 Mar 16];19(1):e9. PMID:28104579 
19.  Attard A, Coulson NS. A thematic analysis of patient communication in Parkinson’s disease online 
support group discussion forums. Computers in Human Behavior 2012;28(2):500–506. [doi: 
10.1016/j.chb.2011.10.022] 
20.  Hanna E, Gough B. Men’s accounts of infertility within their intimate partner relationships: an analysis 
of online forum discussions. Journal of Reproductive and Infant Psychology [Internet] Routledge; 
2017;35(2):150–158. [doi: 10.1080/02646838.2017.1278749] 
21.  Hong Y, Peña-Purcell NC, Ory MG. Outcomes of online support and resources for cancer survivors: A 
systematic literature review. Patient Education and Counseling [Internet] 2012 Mar [cited 2018 Nov 
1];86(3):288–296. PMID:21798685 
22.  Gill PS, Whisnant B. A qualitative assessment of an online support community for ovarian cancer 
patients. Patient related outcome measures [Internet] Dove Press; 2012 [cited 2018 Mar 16];3:51–8. 
PMID:23185122 
23.  Said D, Wanas N. CLUSTERING POSTS IN ONLINE DISCUSSION FORUM THREADS. 
International Journal of Computer Science & Information Technology (IJCSIT) [Internet] 2011 [cited 
2017 Nov 8];3(2). [doi: 10.5121/ijcsit.2011.3201] 
24.  Owen JE, Boxley L, Goldstein MS, Lee JH, Breen N, Rowland JH. Use of Health-Related Online 
Support Groups: Population Data from the California Health Interview Survey Complementary and 
Alternative Medicine Study. Journal of Computer-Mediated Communication [Internet] Blackwell 
Publishing Ltd; 2010 Apr 14 [cited 2017 Nov 1];15(3):427–446. [doi: 10.1111/j.1083-
6101.2010.01501.x] 
25.  Chirtes F, Albu S. Prevention and Restoration of Hearing Loss Associated with the Use of Cisplatin. 
BioMed Research International 2016;2014(July 2014). [doi: 10.1155/2014/925485] 
26.  Eysenbach G, Till JE. Ethical issues in qualitative research on internet communities. BMJ (Clinical 
research ed) [Internet] British Medical Journal Publishing Group; 2001 Nov 10 [cited 2017 Dec 
8];323(7321):1103–5. PMID:11701577 
27.  Sanjib K. Deka NL. Performance evaluation and comparison of the five most used search engines in 
retrieving web resources. Online Information Review 2010;34(5):757–771. PMID:42012058 
28.  Batenburg A, Das E. Virtual Support Communities and Psychological Well-Being: The Role of 
Optimistic and Pessimistic Social Comparison Strategies. Journal of Computer-Mediated 
Communication [Internet] Blackwell Publishing Ltd; 2015 Nov 1 [cited 2017 Nov 1];20(6):585–600. 
[doi: 10.1111/jcc4.12131] 
29.  Braun V, Clarke V. Qualitative Research in Psychology Using thematic analysis in psychology Using 
thematic analysis in psychology. Qualitative Research in Psychology [Internet] 2006 [cited 2017 Dec 
1];3(2):77–101. [doi: 10.1191/1478088706qp063oa] 
30.  Han BI, Lee HW, Kim TY, Lim JS, Shin KS. Tinnitus: Characteristics, Causes, Mechanisms, and 
Treatments. Journal of Clinical Neurology [Internet] 2009 Mar 1 [cited 2018 Mar 12];5(1):11. [doi: 
10.3988/jcn.2009.5.1.11] 
31.  Dille MF, Konrad-Martin D, Gallun F, Helt WJ, Gordon JS, Reavis KM, Bratt GW, Fausti SA. Tinnitus 
Onset Rates from Chemotherapeutic Agents and Ototoxic Antibiotics: Results of a Large Prospective 
Study. Journal of the American Academy of Audiology [Internet] 2010 Jun 1 [cited 2018 Mar 
12];21(6):409–417. PMID:20701838 
32.  Greene JB, Standring R, Siddiqui F, Ahsan SF. Incidence of Cisplatin Induced Ototoxicity in Adults 
with Head and Neck Cancer. Advances in Otolaryngology 2016;2015(2015):1–4.  
33.  Kujansuu E, Rahko T, Punnonen R, Karma P. Evaluation of the hearing loss associated with cis-
platinum treatment by high-frequency audiometry. Gynecologic Oncology 1989;33(3):321–322. [doi: 
10.1016/0090-8258(89)90519-2] 
34.  Saladin SP, Perez RB, Cruz PharmD B, Tasnif PharmD Y, Robert Perez Bianca Cruz CB, Yasar Tasnif 
P. A Review of Ototoxic Medications: Implications for Professionals Working with Consumers with 
Hearing Loss. Journal of the American Deafness and Rehabilitation Association [Internet] 2015 [cited 
2018 Feb 1];49. Available from: http://repository.wcsu.edu/jadara 
35.  Lin Z-M, Young Y-H. Investigating the causes of vertigo in breast cancer survivors. European Archives 
of Oto-Rhino-Laryngology [Internet] 2005 May 18 [cited 2018 Mar 12];262(5):432–436. 
PMID:15378316 
36.  Bisht M, Bist SS. Ototoxicity: the hidden menace. Indian journal of otolaryngology and head and neck 
surgery : official publication of the Association of Otolaryngologists of India [Internet] Springer; 2011 
Jul [cited 2018 Mar 16];63(3):255–9. PMID:22754805 
37.  Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. 
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British 
journal of cancer [Internet] Nature Publishing Group; 1998 Apr [cited 2018 Mar 12];77(8):1355–62. 
PMID:9579846 
38.  Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, 
Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, 
Lipshultz SE, Dolan ME, Travis LB. Comprehensive Audiometric Analysis of Hearing Impairment and 
Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology [Internet] American Society of 
Clinical Oncology; 2016 Aug 10 [cited 2018 Feb 26];34(23):2712–20. PMID:27354478 
39.  Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes 
HS, Fosså SD, Oldenburg J, Travis LB. Impact of long-term serum platinum concentrations on neuro- 
and ototoxicity in Cisplatin-treated survivors of testicular cancer. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology [Internet]  American Society of Clinical 
Oncology; 2012 Jan 20 [cited 2018 Feb 19];30(3):300–7. PMID:22184390 
40.  Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous 
System [Internet] 2008;13(1):27–46. PMID:18346229 
41.  Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK V. Ototoxicity from high-dose use of 
platinum compounds in patients with neuroblastoma. Cancer 2006;107(2):417–422. PMID:16779793 
42.  Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-Associated Ototoxicity: A Review for the Health 
Professional. Journal of Toxicology 2016;2016. PMID:28115933 
43.  Tumolo J. Chemo-induced Hearing Loss: Help Patients Cope with the Aural Effects of Cancer 
Treatment. The Hearing Journal [Internet] 2018 Jan [cited 2018 Jan 15];71(1):26–28. [doi: 
10.1097/01.HJ.0000529840.07085.f3] 
44.  Jayakody DMP, Almeida OP, Speelman CP, Bennett RJ, Moyle TC, Yiannos JM, Friedland PL. 
Association between speech and high-frequency hearing loss and depression, anxiety and stress in older 
adults. Maturitas [Internet] Elsevier; 2018 Apr 1 [cited 2018 Feb 27];110:86–91. [doi: 
10.1016/J.MATURITAS.2018.02.002] 
45.  Ciorba A, Bianchini C, Pelucchi S, Pastore A. The impact of hearing loss on the quality of life of elderly 
adults. Clinical interventions in aging [Internet] Dove Press; 2012 [cited 2018 Feb 19];7:159–63. 
PMID:22791988 
46.  Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD. Hearing loss before 
and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta 
Oncologica [Internet] Informa UK Limited, trading as Taylor & Francis Group; 2018;0(0):1–9. [doi: 
10.1080/0284186X.2018.1433323] 
47.  Zarenoe R, Ledin T. Quality of life in patients with tinnitus and sensorineural hearing loss. B-ENT 
[Internet] 2014 [cited 2018 Mar 12];10(1):41–51. PMID:24765828 
48.  Konrad-Martin D, Poling GL, Garinis AC, Ortiz CE, Hopper J, O’Connell Bennett K, Dille MF. 
Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient 
populations, service gaps, barriers and solutions. International Journal of Audiology [Internet] Taylor & 
Francis; 2017 Nov 20 [cited 2018 Mar 16];1–16. [doi: 10.1080/14992027.2017.1398421] 
 
 
 
